Lilly to Add Suicide Warning to Strattera – Medicaid May shrink $5.5 Billion spending on Schizophrenia Drug Thu, 29 Sep 2005 Reuters reports that Eli Lilly is adding a Black Box suicide warning to the Strattera label. Strattera has been promoted as a “non stimulant” treatment for ADHD. Since ADHD…
ACNP Summary Report Criticized as “Junk Science” Sun, 25 Jan 2004 related links: Reply to ACNP Report – Jonathan Leo, Ph.D. FDA Sham Conflicts of Interest Policy Most of the National press coverage of the controversy swirling around the claims and counter claims about drug suicidal obsessive thinking and behavior…
Are SSRIs and Atypical Antidepressants Safe / Effective for Children / Adolescents/ Neonates? Wed, 2 Mar 2005 The American psychiatric establishment continues to operate within a “head in the sand” culture of denial when confronted with compelling evidence that has been scientifically replicated showing that their prescribing of antidepressants for…
20% Drop in Psych Drugs Prescribed for US Children – WashPost Sat, 8 Oct 2005 The Washington Post reports (below) that prescriptions for antidepressants for children have dropped an unprecedented 20% in the US. A continuing series of substantiated reports and Black Box warnings about an increased risk of suicide,…
Advisory Committee tells FDA: strengthen warnings on SSRI drug labels now Wed, 4 Feb 2004 On February 2, more than 60 families and children from all across America testified at a public FDA advisory committee hearing describing (in 2 minutes) how their children suffered drug-induced harm after being prescribed an…
Leading ADHD Researcher Blows Whistle on Concerta & CHADD Fri, 3 Dec 2004 A newly released report by the Center for Disease Control – Health US 2004–reveals how effective the pharmaceutical industry is in marketing its drugs – whether or not they are beneficial; whether or not they cause severe…
FDA’s Double Standard Re: Advisory Committee Membership Mon, 15 Nov 2004 FDA’s inexplicable actions–the latest being the removal of Dr. Curt Furberg from an FDA advisory committee for alleged "intellectual conflict of interest" – demonstrate hypocracy and intellectual dishonesty. Dr. Furberg independently analyzed the scientific data, concluding: "The result is…
Success in academic psychiatry is not measured in the improvement of patients' mental health, but rather in quantifiable commercial tender.How many grants one brings to the university, how many publications one churns out each year, and how many corporate and professional advisory boards one serves on–and how much money one…
Psychiatry’s most powerful and influential key opinion leaders who belong to the American College of Neuropsychopharmacology (ACNP) have been caught off guard. The ACNP leadership is scrambling to overcome the scorn it has received following public disclosure about multiple breaches of ethics and professional standards of conduct. The College and…
A follow-up to news reports about the conflict of interest scandal that has engulfed not only Dr. Charles Nemeroff, former president and editor in chief of the official journal of the American College of Neuropsychopharmacology, but the College itself.
A notice from The American College of Neuropsychopharmacology, the inner sanctum of biological–predominantly drug-centered psychiatry–informs the
membership of the resignation of Dr. Charles Nemeroff, the Editor-in-Chief of its journal, Neuropsychopharmacology.
The harm done by journals’ failure to protect the integrity of science can hardly be overstated.
